Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
SAN DIEGO March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies. Andrew Ratz, Ph.D., Chief Technical Operations Officer, Neurocrine Biosciences Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 years as an executive at Eli Lilly and Company. He had broad responsibility across Lilly's drug and device development and the delivery of innovative solutions spanning preclinical development through global manufacturing. Dr. Ratz contributed to the successful development and registration of more than 25 medicines across multiple t
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations OfficerPR Newswire
- Neurocrine Biosciences: The Song Remains The Same [Seeking Alpha]Seeking Alpha
- Neurocrine Biosciences (NBIX) had its price target raised by JPMorgan Chase & Co. from $176.00 to $177.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS ForumPR Newswire
- BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)PR Newswire
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 3/17/26 - Form 3
- 3/5/26 - Form 4
- 2/23/26 - Form 4
- NBIX's page on the SEC website